Showing results (141-150 of 223) with videos related to
Sort By:
Pageof 23
Clinical and Translational Radiation Oncology|April 6, 2019
The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancerVincent Esteyrie, Baptiste Gleyzolle, Amélie Lusque, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 TrialJean-Sebastien Frenel, Christophe Le Tourneau, Bert O'Neil, et al.Investigational New Drugs|May 16, 2020
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatmentJean-Pierre Delord, Guillem Argilés, Jerôme Fayette, et al.Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.British Journal of Clinical Pharmacology|February 28, 2019
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patientsFélicien Le Louedec, Catherine Alix-Panabières, Thierry Lafont, et al.The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.Clinical Genitourinary Cancer|February 21, 2017
Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell CarcinomaEdouard Auclin, Camille Bourillon, Eleonora De Maio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 StudyJonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.Nature Cancer|May 1, 2026
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 studyNeeltje Steeghs, Carlos Gomez-Roca, Iphigénie Korakis, et al.Pageof 23